| |
| |
| Exchange: |
N/A |
| Security
Type: |
Common |
| Shares
Out: |
46,500,000 |
| Market
Cap: |
66.03(M) |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$0.4 - $5.18 |
|
| Level
I Sector: |
N/A |
| Level
II Sector: |
N/A |
| Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile Enochian BioSciences is a pre-clinical stage biotechnology company. Co.'s product candidates include: ENOB-HV-01 for autologous Human Immunodeficiency Virus (HIV) curative treatment; ENOB-HV-11 for preventive HIV vaccine; ENOB-HV-12 for therapeutic HIV vaccine; ENOB-HV-21 for HIV natural killer and gamma delta T-cell treatment or cure; ENOB-HV-31 for in vivo gene therapy; ENOB-HB-01 for hijacking Hepatitis B Virus polymerase; ENOB-CV-01 for coronavirus treatment; ENOB-CV-11 for coronavirus prophylaxis; ENOB-FL-01 for influenza treatment; ENOB-FL-11 for influenza prophylaxis; and ENOB-DC-11 for off the shelf dendritic cell vaccine for multiple solid tumors.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
0 |
| Total Buy Value |
$0 |
$0 |
$0 |
$0 |
| Total People Bought |
0 |
0 |
0 |
0 |
| Total Buy Transactions |
0 |
0 |
0 |
0 |
| Total Shares Sold |
0 |
0 |
0 |
0 |
| Total Sell Value |
$0 |
$0 |
$0 |
$0 |
| Total People Sold |
0 |
0 |
0 |
0 |
| Total Sell Transactions |
0 |
0 |
0 |
0 |
| End Date |
2024-03-07 |
2023-12-05 |
2023-06-06 |
2022-06-06 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Puche Luisa |
Chief Financial Officer |
• – – |
2021-12-16 |
4/A |
D |
$0.00 |
$0 |
D/D |
(10,000) |
0 |
|
- |
|
| Weird Science Llc |
|
– – • |
2020-12-14 |
4 |
A |
$0.00 |
$0 |
D/D |
61,249 |
4,961,363 |
|
- |
|
| Dybul Mark |
Executive Vice Chair |
• • – |
2020-12-14 |
4 |
A |
$0.00 |
$0 |
D/D |
180 |
66,196 |
|
- |
|
| William Anderson Wittekind |
10% Owner |
– – • |
2020-12-14 |
4 |
A |
$0.00 |
$0 |
I/I |
61,249 |
4,961,363 |
|
- |
|
| Weird Science Llc |
|
– – • |
2020-05-29 |
4 |
D |
$0.00 |
$0 |
D/D |
(17,545,283) |
4,900,114 |
|
- |
|
| Puche Luisa |
Chief Financial Officer |
• – – |
2020-01-07 |
4 |
OE |
$0.00 |
$0 |
D/D |
5,000 |
5,000 |
|
- |
|
| Weird Science Llc |
|
– – • |
2019-07-30 |
4 |
A |
$0.00 |
$0 |
D/D |
3,631,234 |
22,445,397 |
|
- |
|
| Sindlev Rene |
Director |
– • • |
2019-07-30 |
4 |
OE |
$1.30 |
$4,019,999 |
I/I |
3,092,307 |
9,668,351 |
|
- |
|
| Dybul Mark |
Executive Vice Chair |
• • – |
2019-07-30 |
4 |
A |
$0.00 |
$0 |
D/D |
10,680 |
66,016 |
|
- |
|
| William Anderson Wittekind |
10% Owner |
– – • |
2019-07-30 |
4 |
A |
$0.00 |
$0 |
I/I |
3,631,234 |
22,445,397 |
|
- |
|
| Sindlev Rene |
Director |
– • • |
2019-06-04 |
4 |
B |
$6.70 |
$211,050 |
I/I |
31,500 |
6,576,044 |
2.25 |
- |
|
| Sindlev Rene |
Director |
– • • |
2019-06-03 |
4 |
B |
$6.70 |
$268,000 |
I/I |
40,000 |
6,544,544 |
2.25 |
- |
|
| Sindlev Rene |
Director |
– • • |
2019-05-29 |
4 |
B |
$6.60 |
$132,000 |
I/I |
20,000 |
6,504,544 |
2.25 |
- |
|
| Sindlev Rene |
Director |
– • • |
2019-05-28 |
4/A |
B |
$6.61 |
$239,282 |
I/I |
36,200 |
6,484,544 |
2.25 |
- |
|
| Sindlev Rene |
Director |
– • • |
2019-05-28 |
4 |
B |
$6.61 |
$239,282 |
I/I |
36,200 |
6,479,530 |
2.25 |
- |
|
| Sindlev Rene |
Director |
– • • |
2019-05-24 |
4 |
B |
$6.25 |
$31,338 |
I/I |
5,014 |
6,448,344 |
2.25 |
- |
|
| Sindlev Rene |
Director |
– • • |
2019-05-22 |
4 |
B |
$5.76 |
$2,880 |
I/I |
500 |
6,443,330 |
2.17 |
- |
|
| Sindlev Rene |
Director |
– • • |
2019-05-21 |
4 |
B |
$5.75 |
$115,000 |
I/I |
20,000 |
6,442,830 |
2.25 |
- |
|
| Gronfeldt-Sorensen Henrik |
Director |
– • – |
2019-01-10 |
4 |
B |
$2.00 |
$100,000 |
I/I |
50,000 |
50,000 |
2.1 |
- |
|
| Weird Science Llc |
|
– – • |
2018-12-31 |
4 |
A |
$0.00 |
$0 |
D/D |
1,268,880 |
18,814,163 |
|
- |
|
| William Anderson Wittekind |
Director |
– • • |
2018-12-31 |
4 |
A |
$0.00 |
$0 |
I/I |
1,268,880 |
18,814,163 |
|
- |
|
| Dybul Mark |
Executive Vice Chair |
• • – |
2018-12-31 |
4 |
A |
$0.00 |
$0 |
D/D |
3,732 |
55,336 |
|
- |
|
| Sindlev Rene |
Director |
– • • |
2018-12-27 |
4 |
OE |
$1.30 |
$1,700,001 |
I/I |
1,307,693 |
6,422,830 |
|
- |
|
| Sindlev Rene |
Director |
– • • |
2018-12-27 |
4 |
B |
$8.00 |
$743,744 |
I/I |
92,968 |
5,115,137 |
2.25 |
- |
|
| Leire Eric Jean Marie |
Chief Executive Officer |
– – – |
2018-05-24 |
4 |
B |
$5.25 |
$3,691 |
D/D |
700 |
73,246 |
2.36 |
- |
|
66 Records found
|
|
Page 2 of 3 |
|
|
0.03 (2.07%) 
